Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Five Under 5: Top Oncology Videos for the Week of 2/8

google.com·7h

Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10)

google.com·2d

Karyopharm investors fasten their seatbelts | ApexOnco

google.com·2d

Selective JAK Inhibition in RA vs PV

google.com·2d

Karyopharm Therapeutics Inc. SEC 10-K Report

google.com·2d

Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data ...

google.com·2d

Karyopharm Therapeutics Q4 Earnings Call Highlights

google.com·3d

Karyopharm Therapeutics Inc. Q4 2025 Earnings Call Summary

google.com·3d

Karyopharm (KPTI) Q4 2025 Earnings Call Transcript

google.com·3d

KPTI: 2025 revenue rose, costs fell, and key myelofibrosis trial data is due in March

google.com·3d

Karyopharm Q4 2025 slides: Revenue growth amid pivotal myelofibrosis readout preparations

google.com·3d

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights ...

google.com·3d

Repurposed Drug Shows Promise for Essential Thrombocythemia Treatment

google.com·3d

Active Biotech Year End Report 2025

google.com·3d

Galecto prices $275 million stock offering at $19 per share

google.com·4d

FDA Clears Protocol Update for Tasquinimod in Myelofibrosis Trial

google.com·4d

PharmaEssentia Shores up Supply with $46M Investment in Puerto Rico Plant

google.com·4d

Hema Now: Advancing Care in Myelofibrosis - European Medical Journal

google.com·4d

Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal ...

google.com·4d

ASH 2025: Myelofibrosis Roundup

google.com·4d

Loading...Loading more...